Summary
Intuitive Surgical Inc. (ISRG) reported its second-quarter and year-to-date results for the period ending June 30, 2009. The company demonstrated robust revenue growth driven by a significant increase in surgical procedures performed using its da Vinci Surgical System. Recurring revenue from instruments, accessories, and service also showed strong performance, contributing a substantial portion of total revenue. Despite a slight decrease in system unit sales compared to the prior year, the introduction of the new da Vinci Si model and higher average selling prices positively impacted system revenue. The company maintained strong gross profit margins and managed operating expenses effectively, leading to solid income from operations. Financially, ISRG ended the period with a healthy cash position, though cash from operations saw a decline compared to the previous year, partly due to a significant stock repurchase program. Investments in research and development and technology acquisitions continue, reflecting a commitment to innovation and future growth. The company navigates potential risks related to foreign currency fluctuations and the uncertain landscape of healthcare reforms, while demonstrating continued operational strength and market leadership in robotic surgery.
Financial Highlights
45 data points| Revenue | $260.60M |
| Cost of Revenue | $70.40M |
| Gross Profit | $190.20M |
| R&D Expenses | $23.40M |
| SG&A Expenses | $67.30M |
| Operating Expenses | $90.70M |
| Operating Income | $99.50M |
| Net Income | $62.40M |
| EPS (Basic) | $0.18 |
| EPS (Diluted) | $0.18 |
| Shares Outstanding (Basic) | 341.10M |
| Shares Outstanding (Diluted) | 347.40M |
Key Highlights
- 1Total revenue increased to $260.6 million in Q2 2009 from $219.2 million in Q2 2008, driven by strong procedure growth and recognition of previously deferred revenue related to the da Vinci Si launch.
- 2Recurring revenue (instruments, accessories, and service) grew 33% to $137.1 million in Q2 2009, representing 53% of total revenue, up from 47% in Q2 2008.
- 3Procedure volume saw a significant increase of approximately 52% in Q2 2009 compared to the prior year quarter, highlighting growing adoption of robotic surgery.
- 4The company sold 76 da Vinci Surgical Systems in Q2 2009, down from 85 in Q2 2008, but the introduction of the higher-priced da Vinci Si system and dual-console configurations led to an increase in average selling price.
- 5Operating income increased to $99.5 million in Q2 2009 from $78.2 million in Q2 2008, with operating margin improving to 38% from 36%.
- 6The company repurchased $150 million of its common stock during the first half of 2009 as part of a $300 million authorization, impacting cash flows from financing activities.
- 7Cash, cash equivalents, and investments stood at $902.1 million as of June 30, 2009.